期刊文献+

构建江西省药品认证审评中心审评质量管理规范的探讨 被引量:2

Discussion on Constructing the Review Quality Management Standard of Center for Drug Certification and Evaluation of Jiangxi Provence
下载PDF
导出
摘要 该文从江西省药品认证审评中心从事的审评任务出发,对前期的药品技术审评存在的问题进行总结归纳。提出解决问题的方法,即建立药品和医疗器械审评质量管理规范,让技术审评有章可循,有规可依,同时也阐述了建立技术审评质量管理规范的现实意义。最后,以江西省药品认证审评中心开展技术审评质量管理规范实践为例,介绍了建立药品和医疗器械审评质量管理规范过程,为其他同类型的政府审评工作情况提供参考依据。 Based on the task of Jiangxi Center for Drug Certification and Evaluation,this paper summarizes the problems of drug technical evaluation in the early stage.The method to solve the problem was to set up the technical evaluation quality management standard,so that the technical evaluation has rules to follow,and also expounds the practical significance of setting up the technical evaluation quality management standard.Finally,taking Jiangxi Center for Drug Certification and Evaluation to carry out technical evaluation and quality management practices as an example,introduces the process of establishing the technical evaluation and quality management standard,and provides reference for other similar cases.
作者 李平 万咪容 郭文芬 鄢峰 温雯 熊磊 LI Ping;WAN Mirong;GUO Wenfen;YAN Feng;WEN Wen;XIONG Lei(Jiangxi Center for Drug Certification and Evaluation(Jiangxi Center for Medical Device Evaluation),Nanchang Jiangxi 330001,China)
出处 《药品评价》 CAS 2022年第10期577-580,共4页 Drug Evaluation
关键词 药品和医疗器械 技术审评 质量管理规范 Drugs and medical devices Technical review Quality management specifications
  • 相关文献

参考文献10

二级参考文献60

  • 1王方敏,魏雪芳.对药品注册中生产工艺管理问题的思考[J].中国新药杂志,2004,13(10):865-867. 被引量:7
  • 2董江萍,刘璐,张象麟.中美两国药品注册工作时限管理的比较[J].中国新药杂志,2005,14(1):4-7. 被引量:3
  • 3武志昂,毕开顺.从市场经济角度看药品注册管理[J].中国药师,2007,10(5):489-491. 被引量:3
  • 4Jason P, Peter D, Ian W. Medico legal Essentials in Heal- thcare [ M ]. Churchill Livingstone, 2004.
  • 5Office of Management and Systems of FDA. PDUFA III Five- Year Plan [ EB/OL]. (2003-07-27) [ 2014-11-15 ]. ht- tp ://www. fda. gov/downloads/ForIndustry/UserFees/Pre- scriptionDrugUserFee/UCM176324, pdf.
  • 6CDER of FDA, CBER of FDA. Guidance for Review Staff and Industry:Good Review Management Principles and Prac- tices for PDUFA Products [EB/OL]. (2005-03-15) [2014- 11-15 ]. http://www, fda. gov/downloads/drugs/guidance- complianceregulatoryinformation/guidances/ucm079748, pdf.
  • 7CDER of FDA. The CDER 21st Century Review Process Desk Reference Guide (DRG) [ EB/OL]. (2014-09-10) [ 2014-11-15 ]. http://www, fda. gov/downloads/aboutfda/ centersoffices/officeofmedicalproductsandtobacco/cder/man- ualofpoliciesprocedures/ucm218757, pdf.
  • 8CDER of FDA. Good review practice [ EB/OL]. (2013-12- 02 ) [ 2014-11-15 ]. http ://www. fda. gov/drugs/guidance- complianceregulatoryinformation/ucm118777, htm.
  • 9CDER of FDA. Biologics Procedures (SOPPs) [ EB/OL]. ( 2010-05-19 ) [ 2014-11-15 ]. http ://www. fda. gov/Bio- logicsBloodVaccines/GuidanceComplianceRegulatory- Information/ProceduresSOPPs/default. htm.
  • 10Office of new drugs of FDA. Good review practices ( MAPP 6025.1) [ EB/OL ]. (2012-03-02) [ 2014-11-15 ]. ht- tp ://www. fda. gov/downloads/AboutFDA/CentersOffices/ OfficeofMedicalPr o ductsandTobacco/CDER/ManualofPol- iciesProcedures/ucm082016, pdf.

共引文献48

同被引文献9

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部